Loading...

Humacyte, Inc.

HUMANASDAQ
Healthcare
Biotechnology
$1.80
$0.05(3.15%)

Humacyte, Inc. (HUMA) Financial Performance & Income Statement Overview

Explore the financials of Humacyte, Inc. (HUMA), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
0.00%
Operating Income Growth
-14.34%
14.34%
Net Income Growth
100.00%
100.00%
Operating Cash Flow Growth
-33.85%
33.85%
Operating Margin
-1382.45%
1382.45%
Gross Margin
5.32%
5.32%
Net Profit Margin
-729.07%
729.07%
ROE
307.55%
307.55%
ROIC
-94.50%
94.50%

Humacyte, Inc. (HUMA) Income Statement & Financial Overview

Access detailed annual and quarterly income data for Humacyte, Inc. HUMA financial performance.

MetricQ4 2024Q3 2024Q2 2024Q1 2024
Revenue$7.23M$0.00$0.00$0.00
Cost of Revenue$3.61M$0.00$1.82M$1.79M
Gross Profit$3.61M$0.00-$1.82M-$1.79M
Gross Profit Ratio$0.50$0.00
R&D Expenses$20.66M$22.93M$23.75M$21.26M
SG&A Expenses$11.05M$7.31M$3.92M$3.52M
Operating Expenses$31.70M$30.23M$27.68M$24.79M
Total Costs & Expenses$35.32M$30.23M$29.50M$26.58M
Interest Income$852000.00$911000.00$1.31M$1.03M
Interest Expense$2.51M$2.44M$2.52M$1.82M
Depreciation & Amortization$1.81M$1.81M$1.82M$1.79M
EBITDA-$16.62M-$30.23M-$52.33M-$28.29M
EBITDA Ratio-$2.30
Operating Income-$28.09M-$30.23M-$29.50M-$26.58M
Operating Income Ratio-$3.89
Other Income/Expenses (Net)$7.15M-$8.97M-$27.16M-$5.32M
Income Before Tax-$20.94M-$39.20M-$56.66M-$31.90M
Income Before Tax Ratio-$2.90
Income Tax Expense$0.00$0.00$0.00$1.75M
Net Income-$20.94M-$39.20M-$56.66M-$31.90M
Net Income Ratio-$2.90
EPS$1.08-$0.33-$0.48-$0.29
Diluted EPS$1.08-$0.33-$0.48-$0.29
Weighted Avg Shares Outstanding$118.48M$119.41M$119.17M$108.25M
Weighted Avg Shares Outstanding (Diluted)$118.48M$119.41M$119.17M$108.25M

Financial performance has remained strong, with revenue growing from $0.00 in Q1 2024 to $7.23M in Q4 2024. Gross profit continued to perform well, with margins at 50% in the latest quarter. Operating income reached -$28.09M in Q4 2024, holding a steady -389% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$16.62M. Net income rose to -$20.94M, keeping EPS at $1.08. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;